New horizons for new X Prize head.
|
British biotech company Renovo will launch its IPO Wednesday in a shaky European market.
|
The animal industry is a huge opportunity for biotech.
|
The Open-Source Debate Enters the Genomics Arena.
|
Tech Soundings: Big pharma companies are betting their M&A dollars on functional genomics' promise of simpler clinical trials.
|
There's still plenty of time to get in on GeneSweep, a betting pool run by a genomics software organization to guess the total number of human genes.
|
Report sparks genomics debate
|
Big pharma unlocks genomics
|
Celera's publication of the full human genetic code has biotech investors excited again. The stock soared on Monday, but it's given back most of its gains since then. What's next?
|
Once again, Celera leads the growth that is carrying the biotech sector: protein research. A recent alliance with the government and Compaq gives Celera the advantage of a supercomputer that will analyze complex biological data.
|
Cellomics goes beyond genomics
|
Analysts have high hopes for biotech companies seeking to treat genetic disorders.
|
Why The Red Herring is writing about biotechnology.
|